Drug Trial Radar · NCT06016062
A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
221
Planned (sponsor's estimate)
Start
Sep 14, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of Phase I of this trial is to evaluate the safety, tolerability, maximum tolerated dose (MTD)/maximum administered dose (MAD) of RC148 in patients with locally advanced unresectable or metastatic solid tumors to determine the recommended Phase II dose (RP2D), and the secondary objective is to evaluate the PK and PD characteristics, immunogenicity and preliminary clinical efficacy of RC148. Phase II will primarily evaluate the efficacy of the RC148 combination regimen, and secondarily will assess safety and tolerability, PK characteristics, and immunogenicity. During the trial, investigators will also evaluate the potential correlation of biomarkers with efficacy.
Conditions
- Solid Tumor
Interventions
RC148 MonotherapyDrug
RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
RC148+docetaxel Combination TherapyDrug
RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
RC148+RC48 Combination TherapyDrug
RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle; RC48 will be administered as an IV infusion on Day 1 of each 2-week cycle.
RC148+RC88 Combination TherapyDrug
RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.
RC148/Bevacizumab+RC88 Combination TherapyDrug
RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle; Bevacizumab will be administered as an IV infusion on Day 1 of each 3-week cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I:Maximum tolerated dose (MTD)/Maximum administered dose (MAD)Time frame: Subjects will be treated and observed for DLT through the end of the first cycle (Days 1-28)
- Phase I:DLTTime frame: 28 days after first treatment
- Phase I:The incidence and severity of adverse events (AE)Time frame: From the day of ICF sign to 28/90 days after the day of the last treatment
- Phase I:Recommended Phase 2 dose (RP2D)Time frame: 28 days or 1cycle
- Phase II: ORR, DCR, DoR, PFS based on RECIST v1.1 investigator assessment;Time frame: 15 months
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Anhui, China · Recruiting
Beijing Tiantan Hospital, Capital Medical University
Beijing, China · Recruiting
Beijing University Cancer Hospital
Beijing, China · Recruiting
The Fifth Medical Center of Chinese PLA General Hospital
Beijing, China · Recruiting
Jilin Cancer Hospital
Changchun, China · Recruiting
Hunan Cancer Hospital
Changsha, China · Recruiting
Hunan Second People's Hospital
Changsha, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
The Second Affiliated Hospital of Guilin Medical University
Guilin, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Jinan Central Hospital
Jinan, China · Recruiting
Qilu Hospital of shangdong university
Jinan, China · Recruiting
Shandong Cancer Hospital
Jinan, China · Recruiting
Meizhou People's Hospital
Meizhou, China · Recruiting
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute
Nanning, China · Recruiting
Nanyang City Center Hospital
Nanyang, China · Recruiting
Nanyang Second General Hospital
Nanyang, China · Recruiting
Shanghai Pulmonology Hospital
Shanghai, China · Recruiting
Liaoning Cancer Hospital & Institute
Shenyang, China · Recruiting
Shengjing Hospital of China Medical University
Shenyang, China · Recruiting
Shanxi Provincial Tumor Hospital
Taiyuan, China · Recruiting
Tongji Hospital, Tongji Medical College of HUST, China
Wuhan, China · Recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Wuhan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
Yunnan Cancer Hospital
Yunnan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.